Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review

The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPARgamma) agonists, to treat type 2 diabetes. TZD...

Descripción completa

Detalles Bibliográficos
Autores principales: Desouza, Cyrus V., Shivaswamy, Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411525/
https://www.ncbi.nlm.nih.gov/pubmed/22879786
Descripción
Sumario:The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPARgamma) agonists, to treat type 2 diabetes. TZDs have recently been at the center of a controversy with regards to their cardiovascular safety. Pioglitazone is a TZD which has been shown to be effective in glycemic control by lowering insulin resistance. Pioglitazone also has beneficial effects on lipid metabolism and cardiovascular risk. The safety and efficacy of pioglitazone including its pleotropic effects are discussed at length in this article.

Ejemplares similares